DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Autoimmune Disorder
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Primary Sjögren's Syndrome

Interventions: Drug: branebrutinib placebo
Drug: branebrutinib
Drug: abatacept

First Posted Date: 2019-12-05

Last Posted Date: 2024-01-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 119

Registration Number: NCT04186871

Locations: 🇺🇸
Local Institution - 0083, Spokane, Washington, United States
🇺🇸
Local Institution - 0024, Encino, California, United States
🇫🇷
Local Institution - 0075, Brest, France

and more 71 locations

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986322
Drug: famotidine
Other: BMS-986322 Placebo

First Posted Date: 2019-11-25

Last Posted Date: 2022-05-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 171

Registration Number: NCT04175925

Locations: 🇺🇸
ICON (LPRA) - Lenexa, Lenexa, Kansas, United States

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea

Phase 3

Completed

Conditions: Psoriasis

Interventions: Other: Placebo
Drug: BMS-986165

First Posted Date: 2019-11-18

Last Posted Date: 2023-03-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 220

Registration Number: NCT04167462

Locations: 🇨🇳
Local Institution - 0031, Taipei, Taiwan
🇨🇳
Local Institution - 0012, Jingan, Shanghai, China
🇨🇳
Local Institution - 0014, Beijing, Beijing, China

and more 28 locations

A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy

Completed

Conditions: Hepatocellular Carcinoma

First Posted Date: 2019-11-13

Last Posted Date: 2019-11-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1426

Registration Number: NCT04161911

Locations: 🇺🇸
Bristol Myers Squibb, CORDS Research, Princeton, New Jersey, United States

A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants

Phase 1

Completed

Conditions: Health Participants

Interventions: Drug: BMS-986209
Other: BMS-986209 Placebo
Drug: Itraconazole
Drug: Diltiazem

First Posted Date: 2019-11-07

Last Posted Date: 2022-01-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 114

Registration Number: NCT04154800

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Phase 1

Withdrawn

Conditions: Carcinoma, Non-small Cell Lung Cancer

Interventions: Biological: nivolumab
Biological: docetaxel
Biological: ipilimumab
Drug: lucitanib
Drug: cabozantinib
Biological: ramucirumab

First Posted Date: 2019-11-05

Last Posted Date: 2023-12-19

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT04151563

Locations: 🇷🇴
Local Institution, Timisoara, Romania

A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)

Phase 3

Terminated

Conditions: Urinary Bladder Neoplasms

Interventions: Drug: nivolumab
Other: Placebo
Biological: Bacillus Calmette-Guérin (BCG)

First Posted Date: 2019-11-04

Last Posted Date: 2024-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 13

Registration Number: NCT04149574

Locations: 🇦🇺
Local Institution - 0002, Sydney, New South Wales, Australia
🇦🇷
Local Institution - 0088, Capital Federal, Buenos Aires, Argentina
🇯🇵
Local Institution - 0150, Shinjuku-Ku, Tokyo, Japan

and more 78 locations

An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

Completed

Conditions: Melanoma

Interventions: Drug: nivolumab

First Posted Date: 2019-10-31

Last Posted Date: 2025-01-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 150

Registration Number: NCT04146324

Locations: 🇦🇺
Local Institution, Malvern, Victoria, Australia
🇦🇺
Local Institution - 0006, Woodville South, South Australia, Australia

A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US

Completed

Conditions: Venous Thromboembolism (VTE)

First Posted Date: 2019-10-28

Last Posted Date: 2019-10-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 28000

Registration Number: NCT04141228

Locations: 🇺🇸
Local Institution, Flemington, New Jersey, United States

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Biological: Nivolumab
Drug: Nab-paclitaxel
Biological: Ipilimumab

First Posted Date: 2019-10-21

Last Posted Date: 2022-12-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12

Registration Number: NCT04132817

Locations: 🇺🇸
Local Institution, Dallas, Texas, United States
🇺🇸
Local Institution - 0003, Sacramento, California, United States
🇺🇸
Local Institution - 0009, Aurora, Colorado, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy